Zika virus infection during pregnancy can cause serious birth defects of the brain and eyes, including intracranial calcifications, cerebral or cortical atrophy, chorioretinal abnormalities, and optic nerve abnormalities (1,2). The frequency of these Zika-associated brain and eye defects, based on data from the U.S. Zika Pregnancy and Infant Registry (USZPIR), has been previously reported in aggregate (3,4). This report describes the frequency of individual Zika-associated brain and eye defects among infants from pregnancies with laboratory evidence of confirmed or possible Zika virus infection. Among 6,799 live-born infants in USZPIR born during December 1, 2015–March 31, 2018, 4.6% had any Zika-associated birth defect; in a subgroup of pregnancies with a positive nucleic acid amplification test (NAAT) for Zika virus infection, the percentage was 6.1% of live-born infants. The brain and eye defects most frequently reported included microcephaly, corpus callosum abnormalities, intracranial calcification, abnormal cortical gyral patterns, ventriculomegaly, cerebral or cortical atrophy, chorioretinal abnormalities, and optic nerve abnormalities. Among infants with any Zika-associated birth defect, one third had more than one defect reported. Certain brain and eye defects in an infant might prompt suspicion of prenatal Zika virus infection. These findings can help target surveillance efforts to the most common brain and eye defects associated with Zika virus infection during pregnancy should a Zika virus outbreak reemerge, and might provide a signal to the reemergence of Zika virus, particularly in geographic regions without ongoing comprehensive Zika virus surveillance.
To monitor the impact of the 2015–2017 Zika virus outbreak, CDC, in collaboration with state, local, and territorial health departments, established USZPIR to conduct mother-infant linked longitudinal surveillance of outcomes in pregnant women and infants with laboratory evidence of confirmed or possible Zika virus infection during pregnancy* in the 50 U.S. states, the District of Columbia (DC), U.S. territories, and freely associated states.† Data from this cohort have been published previously (3–5). Pregnancies with an outcome occurring during December 1, 2015–March 31, 2018, were included in USZPIR with data reported as of December 2020 included in this report. Jurisdictions collected prenatal, pregnancy outcome, and follow-up information for infants and children (from birth through age 5 years)§ from medical records in a standardized format. All mother-infant data with an indication of a possible abnormality were reviewed by subject matter experts (which included CDC clinicians and researchers and external consultants); data reviewed included results from neuroimaging, ophthalmologic examinations, and clinical examinations for any criteria based on USZPIR surveillance case definition (6). Cases that met criteria for Zika-associated abnormalities were subsequently reviewed in detail by two or more clinicians (including pediatricians, obstetrician-gynecologists, and clinical geneticists), for confirmation and classification of the individual defect or defects. All discrepancies in classification were discussed and resolved among a panel of experts. Infants who had microcephaly and were not small for gestational age at birth underwent further review; those who met criteria for a potential birth head circumference measurement inaccuracy were not included as having microcephaly in USZPIR.¶ Infants with other abnormal radiographic findings (e.g., mineralizing vasculopathy, and isolated subependymal cysts), which were

---

* Maternal laboratory evidence of confirmed or possible Zika virus infection was defined as 1) Zika virus infection detected by a Zika virus RNA nucleic acid amplification test (NAAT) (e.g., reverse transcription–polymerase chain reaction [RT-PCR]) on any maternal, placental, fetal, or infant specimen (referred to as positive Zika virus NAAT) or 2) detection of recent Zika virus infection or recent unspecified flavivirus infection by serologic tests on a maternal, fetal, or infant specimen (i.e., either positive or equivocal Zika virus immunoglobulin M [IgM] and Zika virus plaque reduction neutralization test [PRNT] titer ≥10, regardless of dengue virus PRNT value; or negative Zika virus IgM, and positive or equivocal dengue virus IgM, and Zika virus PRNT titer ≥10, regardless of dengue virus PRNT titer). Infants with positive or equivocal Zika virus IgM are included, provided a confirmatory PRNT has been performed on a maternal or infant specimen. The use of PRNT for confirmation of Zika virus infection, including during pregnancy, in women and infants, is not routinely recommended in Puerto Rico; dengue virus is endemic and cross-reactivity is considered sufficient to indicate possible Zika virus infection.

† U.S. territories in USZPIR are American Samoa, Puerto Rico, and the U.S. Virgin Islands; freely associated states are Federated States of Micronesia and the Marshall Islands.

§Infants and children in Puerto Rico and the U.S. Virgin Islands are followed through age 5 years; infants and children in U.S. states and DC, and U.S. territories and freely associated states are followed through age 3 years.

¶https://www.researchsquare.com/article/rs-1189991/v1
In this report, the number of infants with any Zika-associated birth defect and enumerated individual brain and eye defects identified in the entire cohort with laboratory evidence of confirmed or possible Zika virus infection from a maternal, placental, fetal, or infant specimen are presented. A subgroup of infants from pregnancies with confirmed Zika virus infection (i.e., positive Zika virus NAAT) are reported to examine whether findings are consistent with the entire cohort.** Zika-associated birth defects among pregnancy losses are reported separately.†† In addition, the frequency of Zika-associated birth defects by location of birth, trimester with first evidence separately.†† In addition, the frequency of Zika-associated birth defect was higher among those with first*** trimester infections (3.8%). Frequency of Zika-associated birth defects in infants was similar among those born to symptomatic (5.3%) and asymptomatic (4.2%) pregnant women; neuroimaging and ophthalmology examinations were reported for 4,086 (60.1%) and 2,456 (36.1%), respectively.

The most frequent structural defects reported among live-born infants and children were microcephaly; corpus callosum abnormalities; intracranial calcification; abnormal cortical gyral patterns; ventriculomegaly; cerebral or cortical atrophy; chorioretinal atrophy, scarring, or pigmentary changes; and optic nerve abnormalities (Table 2). A similar distribution of birth defects was observed in the total cohort and in the Zika virus NAAT-positive subgroup. Among infants with any Zika-associated birth defect, one third (110 of 315) had more than one birth defect identified.

Among 325 pregnancies with laboratory evidence of confirmed or possible Zika virus infection that resulted in a pregnancy loss, 13 (4.0%) fetuses had any reported Zika-associated birth defect. Defects included microcephaly, cerebral or cortical atrophy, abnormal cortical gyral patterns, corpus callosum abnormalities, cerebellar abnormalities, hydranencephaly, ventriculomegaly or hydrocephaly, and brainstem abnormalities (C Moore, CDC, unpublished data, 2022).

** Includes maternal, placental, fetal, or infant laboratory evidence of Zika virus infection based on the presence of Zika virus RNA by a positive NAAT (e.g., RT-PCR),
†† Pregnancy losses include spontaneous abortions, terminations, stillbirths, and pregnancy losses not specified. Information from prenatal or postnatal imaging and autopsy were used to determine presence of Zika-associated birth defects, although pregnancy losses often had less information reported and frequently lacked postnatal imaging that could verify prenatal findings and might identify additional abnormalities.
§§§ Includes maternal, placental, fetal, or infant laboratory evidence of Zika virus infection based on the presence of Zika virus RNA by a positive NAAT (e.g., RT-PCR).
§§ § Includes maternal, placental, fetal, or infant laboratory evidence of Zika virus infection based on the presence of Zika virus RNA by a positive NAAT (e.g., RT-PCR).
§§ §§ Includes maternal, placental, fetal, or infant laboratory evidence of Zika virus infection based on the presence of Zika virus RNA by a positive NAAT (e.g., RT-PCR).
§§§§ Includes maternal, placental, fetal, or infant laboratory evidence of Zika virus infection based on the presence of Zika virus RNA by a positive NAAT (e.g., RT-PCR).
** Signs and symptoms included fever, arthralgia, conjunctivitis, rash, and other clinical signs or symptoms that are consistent with Zika virus disease.
*** Zika virus infections that occurred during the periconceptual period, which is defined as 4 weeks before last menstrual period, are included in the first trimester.

Discussion

During 2015–2017, large Zika virus outbreaks occurred throughout the United States (including U.S. territories and freely associated states). In the United States, infections during pregnancy were initially reported among U.S. travelers returning from affected countries.††† During 2016, widespread local transmission was documented in the territories of Puerto Rico and the U.S. Virgin Islands, and limited transmission was documented in some counties in Florida and Texas.§§§§ Among completed pregnancies with laboratory evidence of Zika virus infection reported to USZPIR, 4.6% of live-born infants had any Zika-associated birth defect. Among the subgroup with NAAT-positive results, Zika-associated birth defects were reported with exposures throughout pregnancy but were more prevalent among infants born to mothers with exposure early in pregnancy. Approximately two thirds of pregnant women in this cohort reported asymptomatic infections.** The similar frequency of Zika-associated birth defects among
TABLE 1. Frequency of Zika-associated birth defects,§ by selected characteristics among live-born infants from pregnancies with laboratory evidence of confirmed or possible Zika virus infection — U.S. Zika Pregnancy and Infant Registry, December 1, 2015–March 31, 2018

| Characteristic                                      | From pregnancies with laboratory evidence of confirmed or possible Zika virus infection¹ | From pregnancies with positive Zika virus NAAT result§ |
|-----------------------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------|
|                                                     | No./Total no. % (95% CI)                                                             | No./Total no. % (95% CI)                             |
| **Total**                                           | 315/6,799 4.6 (4.1–5.2)                                                             | 138/2,257 6.1 (5.1–7.2)                             |
| **Location of birth**                                | 124/2,288 5.4 (4.5–6.5)                                                             | 38/374 10.2 (7.2–14.0)                              |
| U.S. states and DC                                   | 191/4,511 4.2 (3.7–4.9)                                                             | 100/1,883 5.3 (4.3–6.5)                             |
| U.S. territories and freely associated states¶       | 108/2,121 5.1 (4.2–6.2)                                                             | 43/539 8.0 (5.8–10.8)                               |
| **Trimester with first evidence of exposure**)**:††   | 315/6,799 4.6 (4.1–5.2)                                                             | 138/2,257 6.1 (5.1–7.2)                             |
| 1st§§                                               | 124/2,288 5.4 (4.5–6.5)                                                             | 38/374 10.2 (7.2–14.0)                              |
| 2nd                                                 | 191/4,511 4.2 (3.7–4.9)                                                             | 100/1,883 5.3 (4.3–6.5)                             |
| 3rd                                                 | 108/2,121 5.1 (4.2–6.2)                                                             | 43/539 8.0 (5.8–10.8)                               |
| **Maternal symptoms***,*****                        | 124/2,288 5.4 (4.5–6.5)                                                             | 38/374 10.2 (7.2–14.0)                              |
| Signs/Symptoms of Zika virus disease                 | 126/2,379 5.3 (4.4–6.3)                                                             | 92/1,596 5.8 (4.7–7.1)                              |
| No signs/symptoms of Zika virus disease              | 186/4,382 4.2 (3.7–4.9)                                                             | 46/661 7.0 (5.1–9.3)                                |
| **Examinations reported**                            | 258/4,086 6.3 (5.6–7.1)                                                             | 120/1,595 7.5 (6.2–9.0)                             |
| Neuroimaging                                         | 167/2,456 6.8 (5.8–7.9)                                                             | 79/1,072 7.4 (5.8–9.2)                              |

Abbreviations: DC = District of Columbia; NAAT = nucleic acid amplification test; RT-PCR = reverse transcription–polymerase chain reaction reaction; USZPIR = U.S. Zika Pregnancy and Infant Registry.

§ Zika-associated birth defects include selected congenital brain anomalies (intracranial calcifications, cerebral or cortical atrophy, abnormal cortical gyral patterns, corpus callosum abnormalities, cerebellar abnormalities, porencephaly, hydranencephaly, or ventriculomegaly/hydrocephaly); selected congenital eye anomalies (microphthalmia or anophthalmia; coloboma; cataract; intracocular calcifications; chorioretinal anomalies involving the macula, excluding retinopathy of prematurity; and optic nerve atrophy, pallor, and other optic nerve abnormalities); and/or microcephaly at birth (birth head circumference below the third percentile for infant sex and gestational age based on INTERGROWTH-21st online percentile calculator unless infants meet criteria of possible measurement inaccuracy. http://intergrowth21.nog.ox.ac.uk/.

† Includes maternal, placental, or infant laboratory evidence of confirmed or possible Zika virus infection during pregnancy based on presence of Zika virus RNA by a positive NAAT (e.g., RT-PCR), serologic evidence of a Zika virus infection, or serologic evidence of an unspecified flavivirus infection.

‡ Includes maternal, placental, or infant laboratory evidence of confirmed Zika virus infection during pregnancy based on presence of Zika virus RNA by a positive NAAT (e.g., RT-PCR).

¶ U.S. territories in USZPIR are American Samoa, Puerto Rico, and the U.S. Virgin Islands; freely associated states are Federated States of Micronesia and the Marshall Islands.

** Among pregnancies in which birth occurred in the U.S. states and DC, symptom onset date, travel dates to an endemic region, or date of earliest laboratory evidence of Zika virus infection were used to calculate trimester of exposure. Among pregnancies where birth occurred in U.S. territories and freely associated states, symptom onset date or date of earliest laboratory evidence of Zika virus infection were used to calculate trimester of exposure.

†† Unknown trimester of exposure is not shown because of small cell sizes; 144 pregnancies were missing trimester of exposure.

§§ Zika virus infections that occurred during the periconceptual period, which is defined as 4 weeks before last menstrual period, are included in the first trimester of exposure.

*‡‡ Maternal symptom status is not shown because of small cell sizes; 38 pregnancies were missing maternal symptom status.

*** Signs and symptoms included fever, arthralgia, conjunctivitis, rash, and other clinical signs or symptoms that are consistent with Zika virus disease.

The findings in this report are subject to at least five limitations. First, these data are based on information abstracted from medical records. Although CDC provided specific guidance for evaluation of all infants born from pregnancies with possible Zika virus exposure during pregnancy (7), these evaluations might not have been feasible, were not always conducted, or were not found in records (4). Zika-associated birth defects, especially individual brain and eye defects might not have been detected without occurrence and reporting of neuroimaging and ophthalmologic examinations. Second, these findings are only applicable to live births. Pregnancy losses are likely underreported to USZPIR, and among those reported, postnatal studies to verify prenatal findings or identify additional defects are often lacking. Third, although routine testing during pregnancy occurred in areas with local Zika virus transmission, a potential bias could have been introduced in areas without local transmission, as differential testing might have occurred in asymtomatic and symptomatic pregnant women is consistent with previous findings (3,5).

Certain individual brain and eye defects associated with Zika virus infection were frequently reported in USZPIR cohort. A similar subset of Zika-associated birth defects was found to have significantly higher prevalence ratios in areas of widespread local transmission compared with areas without local transmission in the Ziba Birth Defects Surveillance System.**** Given the short window for testing and that symptoms of Zika are often mild or absent, combining these two systems has identified the most prevalent Zika-associated birth defects. Using a surveillance system that monitored outcomes regardless of testing and a system that monitored outcomes among those possibly exposed to Zika virus has been critical to understanding the effects of Zika virus infection during pregnancy on infants and children.

**** https://www.researchsquare.com/article/rs-1189990/v1
TABLE 2. Individual Zika-associated birth defects among live-born infants from pregnancies with laboratory evidence of confirmed or possible Zika virus infection — U.S. Zika Pregnancy and Infant Registry, December 1, 2015–March 31, 2018

| Birth defect                                      | From pregnancies with laboratory evidence of confirmed or possible Zika virus infection* (n = 6,799) | From pregnancies with positive Zika virus NAAT result† (n = 2,257) |
|--------------------------------------------------|---------------------------------------------------------------------------------|------------------------------------------------------------------|
| Any Zika-associated birth defect§                 | 315 (4.6)                                                                       | 138 (6.1)                                                        |
| Brain abnormalities/Microcephaly¶                |                                                                                 |                                                                  |
| Any brain abnormality/microcephaly                | 275 (4.0)                                                                       | 126 (5.6)                                                        |
| Microcephaly**††                                  | 214 (3.1)                                                                       | 100 (4.4)                                                        |
| Corpus callosum abnormalities                     | 64 (0.9)                                                                        | 40 (1.8)                                                         |
| Intracranial calcifications                       | 58 (0.9)                                                                        | 27 (1.2)                                                         |
| Abnormal cortical gyral patterns                  | 56 (0.8)                                                                        | 29 (1.3)                                                         |
| Ventriculomegaly/Hydrocephaly                     | 53 (0.8)                                                                        | 34 (1.5)                                                         |
| Cerebral or cortical atrophy                      | 43 (0.6)                                                                        | 24 (1.1)                                                         |
| Cerebellar abnormalities                          | 27 (0.4)                                                                        | 15 (0.7)                                                         |
| Fetal brain disruption sequence                   | 12 (0.2)                                                                        | 10 (0.4)                                                         |
| Brainstem abnormalities                           | 8 (0.1)                                                                         | 6 (0.3)                                                          |
| Porencephaly/Hydranencecephaly                    | 5 (0.1)                                                                         | 3 (0.1)                                                          |
| Eye abnormalities                                 |                                                                                 |                                                                  |
| Any eye abnormality                               | 76 (1.1)                                                                        | 34 (1.5)                                                         |
| Chorioretinal atrophy, scarring, or pigmenitary changes | 47 (0.7)                                                                       | 25 (1.1)                                                         |
| Optic nerve abnormalities                         | 34 (0.5)                                                                        | 13 (0.6)                                                         |
| Coloboma                                          | 7 (0.1)                                                                         | 5 (0.2)                                                          |
| Congenital cataract                               | 7 (0.1)                                                                         | 3 (0.1)                                                          |
| Microphthalmia                                    | 5 (0.1)                                                                         | 1 (—)                                                            |
| Other brain and eye abnormality patterns          |                                                                                 |                                                                  |
| Multiple brain or eye abnormalities               | 110 (1.6)                                                                       | 55 (2.4)                                                         |
| Brain and eye abnormalities                       | 36 (0.5)                                                                        | 22 (1.0)                                                         |
| One or more brain abnormalities only              | 239 (3.5)                                                                       | 104 (4.6)                                                        |
| One brain abnormality or microcephaly only        | 173 (2.5)                                                                       | 72 (3.2)                                                         |
| Microcephaly only§§                               | 144 (2.1)                                                                       | 58 (2.6)                                                         |
| Microcephaly only and SGA                         | 98 (1.4)                                                                        | 37 (1.6)                                                         |
| One or more eye abnormalities only                | 40 (0.6)                                                                        | 12 (0.5)                                                         |
| One eye abnormality only                          | 32 (0.5)                                                                        | 11 (0.5)                                                         |

Abbreviations: NAAT = nucleic acid amplification test; RT-PCR = reverse transcription–polymerase chain reaction; SGA = small for gestational age.
* Includes maternal, placental, or infant laboratory evidence of confirmed or possible Zika virus infection during pregnancy based on presence of Zika virus RNA by a positive NAAT (e.g., RT-PCR), serologic evidence of a Zika virus infection, or serologic evidence of an unspecified flavivirus infection.
† Includes maternal, placental, or infant laboratory evidence of confirmed Zika virus infection during pregnancy based on presence of Zika virus RNA by a positive NAAT.
‡ Zika-associated birth defects include selected congenital brain anomalies (intracranial calcifications, cerebral or cortical atrophy, abnormal cortical gyral patterns, corpus callosum abnormalities, cerebellar abnormalities, porencephaly, hydranencephaly, or ventriculomegaly/hydrocephaly); selected congenital eye anomalies (microphthalmia or anophthalmia; coloboma; cataract; intraocular calcifications; chorioretinal anomalies involving the macula, excluding retinopathy of prematurity; and optic nerve atrophy, pallor, and other optic nerve abnormalities); and/or microcephaly at birth (birth head circumference below the third percentile for infant sex and gestational age based on INTERGROWTH-21st online percentile calculator unless infants meet criteria of possible measurement inaccuracy. http://intergrowth21.ndog.ox.ac.uk/)
§ Includes maternal, placental, or infant laboratory evidence of confirmed or possible Zika virus infection during pregnancy based on positive NAAT (e.g., RT-PCR), serologic evidence of a Zika virus infection, or serologic evidence of an unspecified flavivirus infection.
¶ Includes maternal, placental, or infant laboratory evidence of confirmed or possible Zika virus infection during pregnancy based on presence of Zika virus RNA by a positive NAAT (e.g., RT-PCR), serologic evidence of a Zika virus infection, or serologic evidence of an unspecified flavivirus infection.
** Includes maternal, placental, or infant laboratory evidence of confirmed or possible Zika virus infection during pregnancy based on presence of Zika virus RNA by a positive NAAT (e.g., RT-PCR), serologic evidence of a Zika virus infection, or serologic evidence of an unspecified flavivirus infection.
†† Among infants with brain abnormalities, microcephaly, or both, 24 (0.4%) and 11 (0.5%) infants also had arthrogryposis among pregnancies with laboratory evidence of confirmed or possible Zika virus infection during pregnancy and NAAT-confirmed Zika virus infection, respectively.
‡‡ Among infants with microcephaly, 141 and 64 also had a birthweight below the 10th percentile (SGA) among pregnancies with laboratory evidence of confirmed or possible Zika virus infection during pregnancy and NAAT-confirmed Zika virus infection, respectively.
§§ Neuroimaging was available for 66.0% and 29.2% of infants with microcephaly only from pregnancies with laboratory evidence of confirmed or possible Zika virus infection during pregnancy and NAAT-confirmed Zika virus infection, respectively.
Summary
What is already known about this topic?
Zika virus infection during pregnancy can cause serious brain and eye birth defects.

What is added by this report?
This study describes the frequency of individual Zika-associated birth defects from the U.S. Zika Pregnancy and Infant Registry (USZPIR). Approximately 5% of infants in USZPIR had any Zika-associated brain or eye defect. Several individual brain and eye defects were more commonly reported. One third of infants with any Zika-associated birth defect had more than one defect reported.

What are the implications for public health practice?
Certain brain and eye defects in infants might prompt suspicion of prenatal Zika virus infection and might provide a signal to the reemergence of Zika virus, particularly in geographic regions without ongoing comprehensive Zika virus surveillance.

Much has been learned since the first infant with Zika-associated birth defects was identified in the United States. This report is the first to describe Zika-associated birth defects from USZPIR with data combined from the U.S. states, DC, and U.S. territories and freely associated states. The study provides a description of the frequency of individual Zika-associated birth defects reported among infants from pregnancies with laboratory evidence of confirmed or possible Zika virus infection. Additional study is needed to define the full spectrum of Zika-associated outcomes, including any specific defects or combination of defects that might predict the presence of Zika virus infection and Zika virus circulation. Further monitoring of these infants for neurodevelopmental abnormalities is ongoing. Infants exposed to Zika virus infection in utero, but without structural birth defects, might also have neurologic sequelae and developmental delay (4, 8). Zika virus outbreaks are tracked globally; Zika virus infection remains a nationally reportable disease in the United States. These findings can help to target surveillance efforts to the most common brain and eye defects associated with Zika virus infection during pregnancy should a Zika virus outbreak reemerge, and might provide a signal to the reemergence of Zika virus, particularly in geographic regions without ongoing comprehensive Zika virus surveillance.

https://ndc.services.cdc.gov/case-definitions/zika-virus-disease-and-zika-virus-infection-2016-06-01/

Acknowledgments
U.S. Zika Pregnancy and Infant Registry surveillance staff members; CDC deployers; health department staff members and clinicians; Rupa Sharma, Catherine Waters, Arkansas Department of Health; Olga Barer, Valerie Eckert, Richard Olney, Similoluwa Sowunmi, Barbara Wärmerdam, California Department of Public Health; Kari Díaz, Chicago Department of Public Health; Jennifer House, Colorado Department of Public Health and Environment; Andrew Hennenfent, Preetha Iyengar, Shreya Khuntia, Sasha McGee, Sarah Warner, District of Columbia Department of Health; Heather Lake-Burger, Joseph Lowry, Florida Department of Health; Michael Bryan, Amanda Feldpausch, Bill Williamson, Georgia Department of Public Health; Hawaii State Department of Health Disease Outbreak Control Division; Paul Afnan, Tahani Hamdan, Tolulope Olumuyiwa, Kirstin Short, Prama Singh, Houston Health Department, Texas; Angela C. Butler, Latina Iverson-Simmons, Julie A. Rowden, Theresa Sandidge, Illinois Department of Public Health; Alexandra Bianco, Jennifer A. Brown, Taryn Condon, Indiana Department of Health; Julie Coughlin, Carrie Fall, Florence Foo, Iowa Department of Public Health; Farah S. Ahmed, Jamie S. Kim, Kansas Department of Health and Environment; Matthew Johnson, Rachel Zinner, Kentucky Department of Public Health; Clara Chang, Umme-Aiman Halai, Mireille Ibrahim, Van P. Ngo, Craig Vincent-Jones, Los Angeles County Department of Public Health; Catherine M. Brown, Julie E. Dunn, Cathleen A. Higgins, Kayleigh Sandhu, Sarah Scotland, Susan Soliva, Mahsa Yazdy, Massachusetts Department of Public Health; Sook Ja Cho, Michele T. Hort, Minnesota Department of Health; John E. Bos, Missouri Department of Health and Senior Services; Jeffrey J. Hamik, Samir Koirala, Nebraska Department of Health and Human Services; Suzann Beauregard, Katrina Hansen, Abigail Mathewson, New Hampshire Department of Health and Human Services; Lisa D’Amico, New Jersey Department of Health; Pauline Santos, New York State Department of Health; Lexi R. Richardson, Oklahoma State Department of Health; Allison Longenberger, Barry Miller, Pennsylvania Department of Health; Amariyis Asencio-Torres, Camille Delgado-López, Mariam Marcano Huertas, Leishia Nieves-Ferrer, Marangeli Olan-Martinez, Stephany Pérez-González, Puerto Rico Department of Health; Edlen Anzuos, Kennar Briand, Ranson Hanson, Jill A. McCready, Republic of the Marshall Islands Ministry of Health and Human Services; Kristen St. John, Rhode Island Department of Health; Devin Raman, Southern Nevada Health District; Carolina Clark, Jacqueline Johnson, Morgan McDonald, Tennessee Department of Health; Rebecca Breidenbach, Kelly Broussard, Kamesha Owens, Texas Department of State Health Services; Cosme Jeremy Harrison, U.S. Virgin Islands Department of Health; Rachael Straver, Virginia Department of Health; Caroline Hayney, Kimberly K. Meinholz, Rebecca A. Osborn, Angela M. Rohan, Wisconsin Department of Health Services.

Corresponding author: Nicole M. Roth, netnet@cdc.gov.

1Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, CDC; 2Eagle Global Scientific, LLC, San Antonio, Texas; 3Puerto Rico Department of Health; 4New York City Department of Health and Mental Hygiene, New York; 5Florida Department of Health; 6Texas Department of State Health Services; 7Houston Health Department, Houston, Texas; 8American Samoa Department of Health; 9U.S. Virgin Islands Department of Health; 10Massachusetts Department of Public Health; 11Los Angeles County Department of Public Health, Los Angeles, California; 12New York State Department of Health; 13Maryland Department of Health; 14Pennsylvania
Department of Health; 15Philadelphia Department of Public Health, Philadelphia, Pennsylvania; 16New Jersey Department of Health; 17Virginia Department of Health; 18Rhode Island Department of Health; 19Kosrae State Department of Health Services, Federated States of Micronesia; 20District of Columbia Department of Health, Washington, DC; 21North Carolina Department of Health and Human Services; 22Washington State Department of Health; 23Illinois Department of Public Health; 24Chicago Department of Public Health, Chicago, Illinois; 25Louisiana Department of Health; 26Colorado Department of Public Health and Environment; 27Ohio Department of Health; 28Utah Department of Health; 29Georgia Department of Public Health; 30Arizona Department of Health Services; 31Wisconsin Department of Health Services; 32Oregon Health Authority; 33Indiana Department of Health; 34Minnesota Department of Health; 35Tennessee Department of Health; 36Arkansas Department of Health; 37Nebraska Department of Health and Human Services; 38Republic of the Marshall Islands Ministry of Health and Human Services; 39South Dakota Department of Health; 40Kentucky Department of Public Health; 41Delaware Health and Social Services; 42Michigan Department of Health and Human Services; 43University of Iowa College of Public Health, Iowa City, Iowa; 44South Carolina Department of Health and Environmental Control; 45Vermont Department of Health; 46Alaska Department of Health and Social Services; 47Kansas Department of Health and Environment; 48New Hampshire Department of Health and Human Services; 49Oklahoma State Department of Health; 50North Dakota Department of Health; 51Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Amanda Elmore reports support from the Florida Birth Defects Registry, Surveillance, Intervention, and Referral to Services for Infants with Microcephaly or Other Adverse Outcomes linked with the Zika Virus in Florida. Jane Fornoff reports that she is vice-chair of the Illinois Department of Public Health’s Institutional Review Board. Nicole D. Longcore reports grant support from Epidemiology and Laboratory Capacity for Infectious Diseases. Amy E. Nance reports that she is co-chair for Communication and Health Promotion of the National Birth Defect Prevention Network. Brennan Martin reports being a member-at-large for the National Birth Defect Prevention Network (2019). No other potential conflicts of interest were disclosed.

References

1. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects—reviewing the evidence for causality. N Engl J Med 2016;374:1981–7. PMID:27074377 https://doi.org/10.1056/NEJMsr1604338
2. Moore CA, Staples JE, Dobyns WB, et al. Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians. JAMA Pediatr 2017;171:288–95. PMID:27812690 https://doi.org/10.1001/jamapediatrics.2016.3982
3. Reynolds MR, Jones AM, Petersen EE, et al.; U.S. Zika Pregnancy Registry Collaboration. Vital signs: update on Zika virus-associated birth defects and evaluation of all U.S. infants with congenital Zika virus exposure—U.S. Zika Pregnancy Registry, 2016. MMWR Morb Mortal Wkly Rep 2017;66:366–73. PMID:28384133 https://doi.org/10.15585/mmwr.mm6613e1
4. Rice ME, Galang RR, Roth NM, et al. Vital signs: Zika-associated birth defects and neurodevelopmental abnormalities possibly associated with congenital Zika virus infection—U.S. territories and freely associated states, 2018. MMWR Morb Mortal Wkly Rep 2018;67:858–67. PMID:30091967 https://doi.org/10.15585/mmwr.mm6731e1
5. Honein MA, Dawson AL, Petersen EE, et al.; US Zika Pregnancy Registry Collaboration. Birth defects among fetuses and infants of US women with evidence of possible Zika virus infection during pregnancy. JAMA 2017;317:59–68. PMID:27960197 https://doi.org/10.1001/jama.2016.19006
6. Olson SM, Delaney A, Jones AM, et al. Updated baseline prevalence of birth defects potentially related to Zika virus infection. Birth Defects Res 2019;111:938–40. PMID:31264801 https://doi.org/10.1002/bdr2.1546
7. Adebamjo T, Godfred-Cato S, Viens L, et al.; Contributors. Update: interim guidance for the diagnosis, evaluation, and management of infants with possible congenital Zika virus infection—United States, October 2017. MMWR Morb Mortal Wkly Rep 2017;66:1089–99. PMID:29049277 https://doi.org/10.15585/mmwr.mm6641a1
8. Honein MA, Woodworth KR, Gregory CJ. Neurodevelopmental abnormalities associated with in utero Zika virus infection in infants and children—the unfolding story. JAMA Pediatr 2020;174:237–8. PMID:31904764 https://doi.org/10.1001/jamapediatrics.2019.5257